glycosyltransferase family 2

glycosyltransferase family 2
Name	Glycosyltransferase family 2
Pfam	PF00535
Interpro	IPR001173
Prosite	PDOC00523
Caption	Representative glycosyltransferase fold

Contents

glycosyltransferase family 2

Glycosyltransferase family 2 comprises a large group of enzymes that catalyze glycosidic bond formation and are central to glycoconjugate biosynthesis. Members participate in pathways found across taxa from bacteria to mammals and interface with processes studied by Isaac Newton, Charles Darwin, Rosalind Franklin, Linus Pauling, Marie Curie as exemplars of cross-disciplinary research, linking structural, genetic, biochemical, and medical investigations. Prominent projects and institutions such as Human Genome Project, Max Planck Society, Cold Spring Harbor Laboratory, Broad Institute, and European Molecular Biology Laboratory have contributed data and methods relevant to this family.

Overview and classification

GT2 enzymes are classified within sequence-based systems developed by repositories like the Carbohydrate-Active enZYmes database and are related conceptually to classifications produced by groups at University of Cambridge, Harvard University, Massachusetts Institute of Technology, Stanford University, and University of Oxford. Family membership unites enzymes such as bacterial cellulose synthases, eukaryotic β-1,4-galactosyltransferases, and dolichyl-phosphate glycosyltransferases studied in models including Escherichia coli, Saccharomyces cerevisiae, Arabidopsis thaliana, Mus musculus, and Homo sapiens. Large-scale surveys by consortia like Genome Canada, National Institutes of Health, European Research Council, and teams at Sanger Institute have expanded GT2 annotations and integrated findings with resources from UniProt, Pfam, InterPro, Ensembl, and KEGG.

Crystal structures and cryo-EM reconstructions produced by laboratories at Rutherford Appleton Laboratory, Diamond Light Source, Max Planck Institute for Biophysical Chemistry, University of California, San Francisco, and Yale University reveal that GT2 members share a conserved catalytic core with variations related to membrane association characterized by studies led by investigators affiliated with Wellcome Trust, Bill & Melinda Gates Foundation, and national centers such as National Center for Biotechnology Information. Mechanistic analyses echo themes from work by Arthur Kornberg and John Kendrew on enzymology and structural biology: nucleoside-diphosphate-sugar donors are coordinated in an active site that orients acceptors for SN2-like displacement, with catalytic residues conserved across divergent clades examined in projects at California Institute of Technology, Imperial College London, University of Chicago, and Princeton University. High-resolution maps from teams at European Synchrotron Radiation Facility and Lawrence Berkeley National Laboratory support proposed transition states and metal ion involvement analogous to observations in studies at Brookhaven National Laboratory.

GT2 enzymes accept diverse donor substrates such as UDP-glucose, GDP-mannose, and UDP-galactose characterized by biochemical screens from laboratories at Cold Spring Harbor Laboratory, Max Planck Institute for Plant Breeding Research, and Johns Hopkins University. Activities include cellulose and chitin synthase functions, β-glucosyltransferase, and galactosyltransferase activities documented in model organisms like Bacillus subtilis, Neurospora crassa, Zea mays, Oryza sativa, and Drosophila melanogaster. Substrate recognition motifs were delineated through mutagenesis and kinetic work in groups at ETH Zurich, University of Toronto, Seoul National University, and Peking University, while inhibitor profiling has been advanced by collaborations with pharmaceutical centers such as Pfizer, Novartis, GlaxoSmithKline, and Merck & Co..

Functionally, GT2 enzymes underlie cellulose biosynthesis in plant cell walls, exopolysaccharide production in bacterial biofilms, and N-linked glycan assembly in eukaryotic secretory pathways—areas investigated in field-defining studies linked to institutions like Royal Botanic Gardens, Kew, USDA, Japanese Science and Technology Agency, and CSIRO. Their roles intersect with developmental biology research at European Molecular Biology Laboratory and Max Planck Institute for Developmental Biology and with immunology and microbiology efforts at Pasteur Institute, Centers for Disease Control and Prevention, and Rockefeller University. GT2-mediated glycoconjugates affect interactions with hosts and pathogens studied in contexts including World Health Organization initiatives, vaccine research at NIH Vaccine Research Center, and agricultural programs at CIMMYT.

Phylogenetic studies combining datasets from projects at Broad Institute, Sanger Institute, JGI (Joint Genome Institute), China National Center for Bioinformation, and NCBI reveal vertical inheritance and horizontal gene transfer events shaping GT2 distribution among bacteria, archaea, plants, fungi, and animals. Comparative analyses leveraging methods from researchers affiliated with Stanford University, University of California, Berkeley, Princeton University, and University of Edinburgh trace diversification into subfamilies associated with specific cellular compartments and organismal lifestyles, paralleling evolutionary frameworks developed by Charles Darwin and synthesized by modern groups at Royal Society meetings.

Mutations and dysregulation of GT2 members are implicated in congenital disorders of glycosylation, microbial virulence phenotypes tracked by World Health Organization, and plant growth defects relevant to agricultural stakeholders like FAO and European Commission. Diagnostic and therapeutic research at Mayo Clinic, Cleveland Clinic, Memorial Sloan Kettering Cancer Center, and MD Anderson Cancer Center explore GT2-linked biomarkers and small-molecule modulators; biotechnological exploitation includes biofuel feedstock engineering by teams at National Renewable Energy Laboratory, carbohydrate-active enzyme optimization at Novozymes, and synthetic biology projects at Synthetic Genomics. Patents and translational programs involve collaborations with industry leaders such as BASF, Bayer, and Dow Chemical Company.

Category:Enzyme families